⌘K

Gates Frontier logo

Gates Frontier

Crunchbase
Pitchbook
Crunchbase

Deals on record

5

Common Fundraising Type

Seed

Lumotive logo
Lumotive

Programmable optical semiconductors • Light Control Metasurface

Swisscom Ventures logo
USAA logo
TSVC logo
Quan Funds logo

Lumotive develops programmable optical semiconductor products using patented Light Control Metasurface technology to enhance perception, computing power, and communication speed across various industries.

Series B
$45M
02/20/2025
Article
Neurophos logo
Neurophos

AI computation • Metasurface

MetaVC logo
Mana Ventures logo
Gates Frontier logo

Neurophos is developing an innovative AI inference acceleration technology by combining optical metasurfaces with silicon photonics to create a more efficient and dense tensor core processor for faster AI computations.

Seed
$7.2M
12/14/2023
Article
Glydways logo
Glydways

Urban Mobility • Personal Rapid Transit

New Science Ventures logo
Khosla Ventures logo
Gates Frontier logo
The ACS Group logo

Glydways is an urban mobility company that provides equitable access to housing, jobs, education, healthcare, and community through their on-demand Personal Rapid Transit (PRT) system called Glydcars, which are autonomous, battery-operated electric vehicles that travel on dedicated rights of way.

Series B
$56M
10/08/2023
Article
Peregrine Hydrogen logo
Peregrine Hydrogen

Climate Technology • Hydrogen Production

Schox logo
RiSC Capital logo
Presidio Ventures logo
Gates Frontier logo

Peregrine Hydrogen is a climate technology company that offers proprietary technology to co-produce clean hydrogen and valuable commodity chemicals, with an initial focus on decarbonizing hydrogen for ammonia production in fertilizer applications.

Seed
$7.8M
09/25/2023
Article
Nimbus Therapeutics logo
Nimbus Therapeutics

Computational Drug Discovery • Immunology

SR One logo
GV logo
Atlas Venture logo
SV Health Investors logo

Nimbus Therapeutics is a clinical-stage company that uses computational chemistry and structure-based drug design to develop novel therapies for immunology, cancer, and metabolic diseases.

Equity
$210M
09/06/2023
Article